NorFoster
Rookie
- Sep 7, 2017
- 2
- 0
- 1
Celgene earnings details. A cut in the outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma company's R&D expenses is not a good sign.
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
The pharma industry is in the business of societal wealth extraction, you don't need to invest in R&D for that.Celgene earnings details. A cut in the outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma company's R&D expenses is not a good sign.